FindMyKOL
Clinical trialNCT05268835UnknownPhase 4Interventional

Different Oral Doses of Clindamycin in Preventing Post-operative Sequelae of Lower Third Molar Surgery

NCT05268835 is a phase 4 interventional trial sponsored by Oral and Maxillofacial Surgery Clinic, Poland. As of 21 Nov 2026, it has a status the registry marks as unknown. It studies Dalacin C in Impacted Molar and Impacted Third Molar Tooth. The registry lists an enrollment of 300 participants at 1 site in 1 country. The registry lists a start date of 1 Feb 2020 and a primary completion date of 31 Aug 2022.

SponsorOral and Maxillofacial Surgery Clinic, PolandEnrollment300Impacted MolarImpacted Third Molar Tooth
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT05268835
FieldValue
Registry IDNCT05268835
StatusUnknown
PhasePhase 4
Study typeInterventional trial
Lead sponsorOral and Maxillofacial Surgery Clinic, Poland
Enrollment300
Registered sites1
Countries1
ConditionsImpacted Molar and Impacted Third Molar Tooth
DrugsDalacin C
Start1 Feb 2020
Primary completion31 Aug 2022
Study completion31 Oct 2022
Last update posted7 Mar 2022

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The objective of the study is to determine the effect of antibiotic prophylaxis with three different doses of clindamycin on preventing infection and other complications after surgical extraction of impacted mandibular third molars.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Poland1 site, 1 recruiting
  • Omfs Clinic

    Zgierz

    Anna Janas-Naze, DMD,PhD,Prof
    Recruiting

Sites by country

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Dalacin C
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT05268835

Each answer restates registry values shown on this page.

What is NCT05268835?

NCT05268835 is a phase 4 interventional trial sponsored by Oral and Maxillofacial Surgery Clinic, Poland. It studies Dalacin C in Impacted Molar and Impacted Third Molar Tooth.

Who leads NCT05268835?

The registry names Anna Janas-Naze, DMD,PhD,Prof (principal investigator, OMFS Clinic) as the overall official.

Where does NCT05268835 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: Poland.

Which drugs does NCT05268835 study?

The registered drug and biological interventions are Dalacin C.

When is NCT05268835 expected to complete?

The registry lists a primary completion date of 31 Aug 2022 and a study completion date of 31 Oct 2022. The sponsor last updated the record on 7 Mar 2022.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.